英夫利西与银屑病的相关研究进展  

New advances of infliximab in psoriasis

作　　者：陈传杰[1] 陆春[1] 

机构地区：[1]中山大学附属第三医院皮肤性病科,广东广州510630

出　　处：《中国新药与临床杂志》2009年第3期167-170,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：英夫利西系肿瘤坏死因子α的人鼠嵌合IgG单克隆抗体,是一种新型治疗自身免疫性疾病的生物制剂,通过抑制肿瘤坏死因子α发挥治疗作用,被较多地应用于类风湿性关节炎及其他自身免疫性疾病,后来用于银屑病的治疗。但近年来发现其在治疗疾病的同时有诱发银屑病现象,本文就英夫利西治疗及致银屑病的研究进行综述。Infliximab, a mouse/human chimeric antibody comprising a mouse variable region and a human IgG1 constant region, used for immune-mediated inflammatory disorders nowadays is a new biologic agent binding specifically to human tumor necrosis factor alpha. Then researchers found infliximab also has satisfactory therapeutic effect on psoriasis. Recently scientists found infliximab could induce psoriasis when it was used for immune-mediated inflammatory disorders. The phenomenon that infliximab which is used for psoriasis can also cause psoriasis is being reviewed herein.

关 键 词：免疫抑制剂 肿瘤坏死因子Α 银屑病 英夫利西 

分 类 号：R986[医药卫生—药品]